Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
宾夕法尼亚州沃明斯特，2024年5月7日（GLOBE NEWSWIRE）——Arbutus Biopharma Corporation（纳斯达克股票代码：ABUS）是一家临床阶段的生物制药公司，利用其广泛的病毒学专业知识为慢性乙型肝炎病毒（ChbV）感染患者开发功能性治疗方法，今天宣布，Arbutus管理团队将参加并主持即将举行的以下两次投资者会议的一对一会议在纽约举行：
- The Citizens JMP Life Sciences Conference: Fireside Chat on May 14, 2024 at 9:30 am ET
- H.C. Wainwright 2nd Annual BioConnect Investor Conference: Fireside Chat on May 20, 2024 at 3:30 pm ET
- Citizens JMP 生命科学会议：美国东部时间 2024 年 5 月 14 日上午 9:30 的炉边谈话
- H.C. Wainwright 2和 年度BioConnect投资者大会：美国东部时间2024年5月20日下午 3:30 的炉边谈话
To access the live webcast of the fireside chats please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
要观看炉边聊天的网络直播，请访问： https://investor.arbutusbio.com/events-presentations。活动结束后的有限时间内，将在Arbutus网站上提供网络直播的存档重播。
About Arbutus
关于 Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Arbutus Biopharma Corporation（纳斯达克股票代码：ABUS）是一家临床阶段的生物制药公司，利用其丰富的病毒学专业知识来识别和开发具有不同作用机制的新型疗法，这些疗法可以结合为慢性乙型肝炎病毒（ChbV）患者提供功能性治愈。我们认为，成功开发功能性治疗方法的关键是抑制乙肝病毒DNA、减少表面抗原和增强乙肝病毒特异性免疫反应。我们内部开发的专有化合物产品线包括一种核糖核酸治疗药物 imdusiran (AB-729) 和口服 PD-L1 抑制剂 AB-101。Imdusiran已经生成了有意义的临床数据，表明它对表面抗原的减少和乙肝病毒特异性免疫反应的恢复都有影响。Imdusiran目前正在进行三项2a期联合临床试验。AB-101 目前正在 1a/1b 期临床试验中进行评估。欲了解更多信息，请访问 www.arbutusbio.com。
Contact Information
联系信息
Investors and Media
投资者和媒体
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
丽莎·M·卡佩雷利
投资者关系副总裁
电话：215-206-1822
电子邮件： lcaperelli@arbutusbio.com
译文内容由第三方软件翻译。